keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasis quality of life

keyword
https://www.readbyqxmd.com/read/28514463/pediatric-psoriasis-comorbidity-screening-guidelines
#1
Emily Osier, Audrey S Wang, Megha M Tollefson, Kelly M Cordoro, Stephen R Daniels, Andrew Eichenfield, Joel M Gelfand, Alice B Gottlieb, Alexa B Kimball, Mark Lebwohl, Nehal N Mehta, Amy S Paller, Jeffrey B Schwimmer, Dennis M Styne, Abby S Van Voorhees, Wynnis L Tom, Lawrence F Eichenfield
Importance: Psoriasis is a complex inflammatory skin condition associated with serious medical comorbidities in adults, including obesity, hypertension, dyslipidemia, type 2 diabetes mellitus, psoriatic arthritis, nonalcoholic fatty liver disease, depression, anxiety, and decreased quality of life. Because psoriasis begins in childhood in almost one-third of patients, early identification of risk may be critical to minimizing effects on future health. Objective: To develop the first set of guidelines for comorbidity screening for patients with pediatric psoriasis based on current evidence...
May 17, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28507445/evaluation-of-fatigue-and-its-correlation-with-quality-of-life-index-anxiety-symptoms-depression-and-activity-of-disease-in-patients-with-psoriatic-arthritis
#2
Claudio Carneiro, Mario Chaves, Gustavo Verardino, Ana Paula Frade, Pedro Guimaraes Coscarelli, Washington Alves Bianchi, Marcia Ramos-E-Silva, Sueli Carneiro
BACKGROUND: Psoriatic arthritis is associated with psychosocial morbidity and decrease in quality of life. Psychiatric comorbidity also plays an important role in the impairment of quality of life and onset of fatigue. OBJECTIVES: This study aimed to assess the prevalence of fatigue in psoriatic arthritis patients and to correlate it to quality of life indexes, functional capacity, anxiety, depression and disease activity. PATIENTS AND METHODS: This cross-sectional study was performed on outpatients with psoriatic arthritis...
2017: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/28506228/chinese-herbal-pulian-ointment-in-treating-psoriasis-vulgaris-of-blood-heat-syndrome-a-multi-center-double-blind-randomized-placebo-controlled-trial
#3
Nuo Li, Wenbin Zhao, Jianmin Xing, Jianping Liu, Guangzhong Zhang, Yunbi Zhang, Yuanwen Li, Wali Liu, Fei Shi, Yanping Bai
BACKGROUND: Traditional Chinese medicine (TCM) has a long history in the treatment of psoriasis vulgaris. We aimed to evaluate the clinical efficacy and safety of Chinese herbal Pulian ointment in treating psoriasis vulgaris of blood-heat syndrome. METHODS: A multicenter, randomized, double-blind, placebo-controlled trial was conducted. Participants with psoriasis vulgaris of blood-heat syndrome were blinded and randomized to receive Pulian ointment or placebo ointment twice daily for 4 weeks, with follow-up 8 weeks after treatment...
May 15, 2017: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/28489479/biologics-and-dermatology-life-quality-index-dlqi-in-the-australasian-psoriasis-population
#4
Diana Norris, Louise Photiou, Mark Tacey, Con Dolianitis, George Varigos, Peter Foley, Chris Baker
BACKGROUND/OBJECTIVES: Psoriasis is a chronic condition that may require long-term treatment for disease control. This analysis utilises data from the Australasian Psoriasis Registry with particular attention to the impact of biologic therapy on DLQI, and the differences between the biologics in terms of DLQI score change. METHODS: A retrospective review of patients enrolled in the Australasian Psoriasis Registry from April 2008 to August 2016 was conducted. All subjects from the registry that had DLQI and Psoriasis Assessment Severity Index (PASI) scores recorded at a baseline timepoint of treatment commencement, in addition to week 12 and 24 post commencement were included in the study...
May 10, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28486717/psoriasis-depression-and-suicidality
#5
M N Nicholas, M Gooderham
Psoriasis is a chronic condition that affects the well-being and quality of life of patients. The disease is associated with an increased risk of depression and suicidality, which may not be fully understood by the general population. It is crucial to understand the effect this disease has on mental health and determine risk factors that may help identify patients who are susceptible to depression and suicidality. Risk factors discussed in this article include age, gender, and severity of disease in psoriasis patients...
May 2017: Skin Therapy Letter
https://www.readbyqxmd.com/read/28482858/tight-controlled-dose-reduction-of-biologics-in-psoriasis-patients-with-low-disease-activity-a-randomized-pragmatic-non-inferiority-trial
#6
Selma Atalay, Juul M P A van den Reek, Lieke J van Vugt, Marisol E Otero, Peter C M van de Kerkhof, Alfons A den Broeder, Wietske Kievit, Elke M G J de Jong
BACKGROUND: Psoriasis is an immune-mediated chronic inflammatory skin disorder for which several targeted biologic therapies became available in the last 10 years. Data from patients with rheumatoid arthritis revealed that dose tapering combined with tight control of disease activity is successful. For psoriasis patients the lowest effective dose of biologics needs to be determined. The objective was to assess whether dose tapering of biologics guided by Psoriasis Area and Severity Index (PASI) and Dermatology Quality of Life Index (DLQI) scores in psoriasis patients with controlled disease activity is non-inferior (NI) to usual care...
May 8, 2017: BMC Dermatology
https://www.readbyqxmd.com/read/28474705/-quality-of-life-in-patients-with-psoriasis
#7
Liliana García-Sánchez, Álvaro José Montiel-Jarquín, Eduardo Vázquez-Cruz, Adriana May-Salazar, Itzel Gutiérrez-Gabriel, Jorge Loría-Castellanoso
INTRODUCTION: Psoriasis is a chronic inflammatory skin disease, in which an autoimmune mechanism participates, triggering an accelerated keratopoiesis. Its etiology is unknown; environmental factors, trauma, and infections are involved. The aim of this paper is to present the correlation between the index of severity of psoriasis and quality of life in patients with psoriasis. METHODS: This was a cross-sectional study in 72 patients with psoriasis, older than 15 years old, who agreed to participate in the study...
March 2017: Gaceta Médica de México
https://www.readbyqxmd.com/read/28464025/pams-ameliorates-the-imiquimod-induced-psoriasis-like-skin-disease-in-mice-by-inhibition-of-translocation-of-nf-%C3%AE%C2%BAb-and-production-of-inflammatory-cytokines
#8
Rongkun Dou, Zongying Liu, Xue Yuan, Danzhou Xiangfei, Ruixue Bai, Zhenfei Bi, Piao Yang, Yalan Yang, Yinsong Dong, Wei Su, Diqiang Li, Canquan Mao
Psoriasis is a chronic and persistent inflammatory skin disease seriously affecting the quality of human life. In this study, we reported an ancient formula of Chinese folk medicine, the natural plant antimicrobial solution (PAMs) for its anti-inflammatory effects and proposed the primary mechanisms on inhibiting the inflammatory response in TNF-α/IFN-γ-induced HaCaT cells and imiquimod-induced psoriasis-like skin disease mouse model. Two main functional components of hydroxysafflor Yellow A and allantoin in PAMs were quantified by HPLC to be 94...
2017: PloS One
https://www.readbyqxmd.com/read/28461763/emerging-targeted-therapies-for-plaque-psoriasis-impact-of-ixekizumab
#9
REVIEW
Tiana Kazemi, Benjamin Farahnik, John Koo, Kourosh Beroukhim
BACKGROUND: Recent studies into the pathogenesis of psoriasis have identified the importance of interleukin 17 (IL-17) in disease activity and have thus provided a new target for biologic therapy. Ixekizumab, the most recent US Food and Drug Administration (FDA)-approved anti-IL-17 biologic agent, appears to be a promising medication for patients suffering from moderate-to-severe plaque psoriasis. METHODS: We reviewed the results of phase III trials for ixekizumab in order to assess the efficacy, safety, and impact on quality of life of this agent in the treatment of plaque psoriasis...
2017: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/28458428/a-study-of-the-use-of-drugs-in-patients-suffering-from-psoriasis-and-their-impact-on-quality-of-life
#10
V V Karamata, A M Gandhi, P P Patel, A Sutaria, M K Desai
OBJECTIVE: To study the use of drugs in patients suffering from psoriasis and their effect on quality of life (QOL). MATERIALS AND METHODS: This was a prospective, observational study carried out in newly diagnosed patient of psoriasis at Department of Pharmacology and Outpatient Department of Skin and Venereal diseases at tertiary care teaching hospital, and patients were divided into three groups: Group A: topical therapy alone, Group B: methotrexate with topical therapy, and Group C: cyclosporine with topical therapy...
January 2017: Indian Journal of Pharmacology
https://www.readbyqxmd.com/read/28452100/pediatric-psoriasis-should-we-be-concerned-with-comorbidities-a-cross-sectional-study
#11
A Kelati, H Baybay, A Najdi, S Zinoune, F Z Mernissi
BACKGROUND: Similarly to psoriasis in adult, Recent research has linked psoriasis to several comorbidities in children. Our objective was to describe comorbidities associated with pediatric psoriasis, to investigate their relationship with psoriasis characteristics and severity, and to perform a review of the literature. METHODS: A cross-sectional study was performed on a sample of Moroccan psoriatic children, during two years 2014 -2016. RESULTS: 64 psoriatic children had metabolic comorbidities in association with psoriasis, 20 children had non-metabolic comorbidities and 76 children didn't have any comorbidities...
April 28, 2017: Pediatrics International: Official Journal of the Japan Pediatric Society
https://www.readbyqxmd.com/read/28426906/measuring-the-impact-of-dermatological-conditions-on-family-and-caregivers-a-review-of-dermatology-specific-instruments
#12
REVIEW
F Sampogna, A Y Finlay, S S Salek, P Chernyshov, F J Dalgard, A W M Evers, D Linder, L Manolache, S E Marron, F Poot, S Spillekom-van Koulil, Å Svensson, J C Szepietowski, L Tomas-Aragones, D Abeni
The patient is the centre of a web of relationships and the impact of his/her disease on family members and caregivers must be taken into account. The aim of this study was to identify the specific instruments that measure the impact of a dermatological disease on the quality of life (QoL) of family members, by performing a systematic search of the literature. Fifteen papers were identified, describing the creation and validation of nine instruments. Four of them concerned atopic dermatitis (Dermatitis Family Index, DFI; Parents' Index QoL Atopic Dermatitis, PiQoL-AD; QoL in Primary Caregivers of children with Atopic Dermatitis, QPCAD; Childhood Atopic Dermatits Impact Scale, CADIS), two measured the impact of psoriasis in family members (Psoriasis Family Index, PFI; FamilyPso), one the impact of epidermolysis bullosa (Epidermolysis Bullosa Burden of Disease, EB-BoD), one of ichthyosis (Family Burden Ichthyosis, FBI), and one was generic for dermatological conditions (Family Dermatology Life Quality Index, FDLQI)...
April 20, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28426138/incremental-burden-of-cardiovascular-comorbidity-and-psoriatic-arthritis-among-adults-with-moderate-to-severe-psoriasis-in-five-european-countries
#13
M Augustin, J Vietri, H Tian, I Gilloteau
BACKGROUND: Moderate-to-severe psoriasis is associated with reduced health-related quality of life (HRQoL). Individuals with psoriasis are at increased risk for other medical conditions, but little information quantifies the incremental burden of psoriasis-associated comorbidity among European adults, and data have generally been limited to clinical samples. OBJECTIVE: To quantify the incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in the general population of France, Germany, Italy, Spain, and the United Kingdom (EU5)...
April 20, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28421729/effects-of-tnf-%C3%AE-inhibitors-in-patients-with-psoriasis-and-metabolic-syndrome-a-preliminary-study
#14
Giulia Merlo, Emanuele Cozzani, Martina Burlando, Stefano Calvieri, Concetta Potenza, Luca Stingeni, Giorgio Filosa, Monica Pau, Marco Simonacci, Marzia Caproni, Aurora Parodi
BACKGROUND: Psoriasis is an inflammatory disease, that is increasingly being considered as a systemic disorder. Among associated comorbidities, metabolic syndrome plays an important role. The effects of biological therapies on metabolic syndrome is controversial. METHODS: Thirty-one psoriatic patients with metabolic syndrome, eligible to treatment with anti-TNFα agents, were enrolled. Metabolic parameters were measured during 4 subsequent visits, one every 40 to 60 days...
April 19, 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/28407292/internalized-stigma-in-psoriasis-a-multicenter-study
#15
Erkan Alpsoy, Mualla Polat, Bilge FettahlıoGlu-Karaman, Ayse Serap Karadag, Pelin Kartal-Durmazlar, Basak YalCın, Selma Emre, Didem Didar-Balcı, Asli Bilgic-Temel, Ercan Arca, Rafet Koca, Kamer Gunduz, Murat Borlu, Tulin Ergun, Seval Dogruk-Kacar, Ayca Cordan-Yazici, Pınar Dursun, Ozlem BilgiC, Serap Gunes-Bilgili, Neslihan Sendur, Ozge Baysal, Ibrahim Halil-Yavuz, Gizem Yagcioglu, Ertan Yilmaz, Ufuk Kavuzlu, Yesim Senol
Internalized stigma is the adoption of negative attitudes and stereotypes of the society regarding a person's illness. It causes decreased self-esteem and life-satisfaction, increased depression and suicidality, and difficulty in coping with the illness. The primary aim of this study was to investigate the internalized stigma state of psoriatic patients and to identify the factors influencing internalized stigma. The secondary aim was to identify the correlation of internalized stigma with quality of life and perceived health status...
April 13, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28403510/-new-to-me-changing-patient-understanding-of-psoriasis-and-identifying-mechanisms-of-change-the-pso-well-%C3%A2-patient-materials-mixed-methods-feasibility-study
#16
P A Nelson, K Kane, C J Pearce, C Bundy, A Chisholm, R Hilton, R Thorneloe, H Young, C E M Griffiths, L Cordingley
BACKGROUND: Psoriasis is an inflammatory, long-term condition (LTC) involving co-morbidities, unhealthy lifestyle and significant life impact. Patients' understanding of psoriasis is limited and support lacking. The Common-Sense Self-Regulatory Model emphasises the role of illness/treatment beliefs on coping/self-management. New 'Pso Well(®) ' patient materials informed by the model addressed: psoriasis as a LTC; medications management; and lifestyle behaviours. OBJECTIVES: To investigate whether Pso Well(®) materials: 1) broaden understanding of psoriasis without increasing anxiety; 2) are acceptable and; 3) comprise features that appear to effect change...
April 12, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28403245/author-paper-affiliation-network-architecture-influences-the-methodological-quality-of-systematic-reviews-and-meta-analyses-of-psoriasis
#17
Juan Luis Sanz-Cabanillas, Juan Ruano, Francisco Gomez-Garcia, Patricia Alcalde-Mellado, Jesus Gay-Mimbrera, Macarena Aguilar-Luque, Beatriz Maestre-Lopez, Marcelino Gonzalez-Padilla, Pedro J Carmona-Fernandez, Antonio Velez Garcia-Nieto, Beatriz Isla-Tejera
Moderate-to-severe psoriasis is associated with significant comorbidity, an impaired quality of life, and increased medical costs, including those associated with treatments. Systematic reviews (SRs) and meta-analyses (MAs) of randomized clinical trials are considered two of the best approaches to the summarization of high-quality evidence. However, methodological bias can reduce the validity of conclusions from these types of studies and subsequently impair the quality of decision making. As co-authorship is among the most well-documented forms of research collaboration, the present study aimed to explore whether authors' collaboration methods might influence the methodological quality of SRs and MAs of psoriasis...
2017: PloS One
https://www.readbyqxmd.com/read/28400641/secukinumab-first-in-class-interleukin-17a-inhibitor-for-the-treatment-of-psoriasis
#18
Kiran Godse
Psoriasis is a complex inflammatory disease that occurs in genetically susceptible individuals and presents with the development of erythematous scaly plaques on the skin. Interleukins (ILs) in the Th17 pathway play a pivotal role in the pathogenesis of psoriasis and have thus become targets for recent biologic drug development. Secukinumab is a human monoclonal IgG1k antibody that has been developed to target and block the actions of IL-17A. Secukinumab recently approved for use as first-line systemic therapy in a patient with moderate to severe psoriasis has been studied first in psoriasis before other diseases...
March 2017: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/28395376/-rehabilitation-of-children-and-adolescents-with-chronic-skin-diseases
#19
R Stachow, M Küppers-Chinnow, S Scheewe
Chronic skin diseases are a common indication for inpatient rehabilitation in children and adolescents. Atopic eczema and psoriasis play the most important role. But other rare congenital dermatoses such as ichthyoses or epidermolysis bullosa can also be rehabilitated. Patients with skin diseases are often considerably stigmatized and report a limited quality of life and participation. The somatic and psychosocial development of the children is also often severely affected by severe forms of the diseases. The concept of inpatient rehabilitation is, on the one hand, the development of an individually adapted topical therapy plan, which often follows a step concept and is adapted to the severity of the skin symptoms...
April 2017: Die Rehabilitation
https://www.readbyqxmd.com/read/28369707/comparative-effectiveness-of-biologic-therapies-on-improvements-in-quality-of-life-in-patients-with-psoriasis
#20
I Y K Iskandar, D M Ashcroft, R B Warren, M Lunt, K McElhone, C H Smith, N J Reynolds, C E M Griffiths
BACKGROUND: Evidence of the comparative effectiveness of biologic therapies for psoriasis on health related quality of life (HRQoL) in routine clinical practice is limited. OBJECTIVES: To examine the comparative effectiveness of adalimumab, etanercept and ustekinumab on HRQoL in psoriasis patients, and to identify potential predictors for improved HRQoL. METHOD: Prospective cohort study in which changes in HRQoL were assessed using the Dermatology Life Quality Index (DLQI) and EuroQoL-5D (EQ-5D) at 6 and 12 months...
March 30, 2017: British Journal of Dermatology
keyword
keyword
65639
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"